专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012088461A3 LINKER PEPTIDES AND POLYPEPTIDES COMPRISING SAME 审中-公开
标题翻译：连接蛋白和包含其的多肽
公开(公告)号：WO2012088461A3
公开(公告)日：2012-12-20
申请号：PCT/US2011066947
申请日：2011-12-22
申请人： BIOGEN IDEC INC , MILLER BRIAN ROBERT , GLASER SCOTT , CARAVELLA JUSTIN , FOLEY SUSAN , HRONOWSKI XIAOPING , AIVAZIAN TIGRAN DIKRAN
发明人： MILLER BRIAN ROBERT , GLASER SCOTT , CARAVELLA JUSTIN , FOLEY SUSAN , HRONOWSKI XIAOPING , AIVAZIAN TIGRAN DIKRAN
IPC分类号： C12N15/62 , C07K16/46
CPC分类号： C07K7/08 , C07K16/241 , C07K16/2875 , C07K16/468 , C07K2317/31 , C07K2317/51 , C07K2317/622 , C07K2317/64 , C07K2317/94 , C07K2319/00 , C12N15/62
摘要： The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.
摘要翻译：本发明至少部分地基于如下发现：缺乏氨基酸序列GSG的接头肽减少或消除了对构成它们的多肽的翻译后修饰的添加。更具体地，本文公开的新型接头肽降低酶将碳水化合物加合物与包含这些接头肽的多肽连接的能力，例如降低木糖基转移酶将木糖与多肽连接的能力。描述了这些新的接头肽，包含其的分子及其使用方法。

2. 发明申请

WO2006074399A2 MULTISPECIFIC BINDING MOLECULES COMPRISING CONNECTING PEPTIDES 审中-公开
标题翻译：包含连接肽的多重结合分子
公开(公告)号：WO2006074399A2
公开(公告)日：2006-07-13
申请号：PCT/US2006/000505
申请日：2006-01-05
申请人： BIOGEN IDEC MA INC. , GLASER, Scott , WU, Xiufeng
发明人： GLASER, Scott , WU, Xiufeng
CPC分类号： C07K16/2878 , C07K16/2875 , C07K16/468 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/624
摘要： The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to pertains to compositions in which a majority of the multispecific binding molecules comrpsing polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.
摘要翻译：本发明描述了包含合成连接肽的新型多特异性结合分子。合成连接肽导致包含通过至少一个链间二硫键连接的多肽链的多特异性结合分子的优先合成。此外，本发明涉及组合物，其中大多数多特异性结合分子包含多肽链，其通过至少一个链间二硫键连接或不通过至少一个链内二硫键连接。在一个具体实施方案中，本发明涉及包含多特异性二聚结合分子的组合物，所述分子包含至少对肿瘤坏死因子（TNF）受体或TNF受体家族成员的配体和至少第二结合位点特异的第一结合位点 ; 和包含至少一个重链部分和合成连接肽的至少两条多肽链; 其中大于约50％的二聚体包含通过至少一个链间二硫键连接的多肽链。

3. 发明申请

WO2004066933A3 COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1 审中-公开
标题翻译：使用IGSF9和LIV-1治疗癌症的组合物和方法
公开(公告)号：WO2004066933A3
公开(公告)日：2006-03-02
申请号：PCT/US2004002044
申请日：2004-01-27
申请人： BIOGEN IDEC INC , MCLACHLAN KAREN , GLASER SCOTT , PEACH ROBERT J , ROWE TONY
发明人： MCLACHLAN KAREN , GLASER SCOTT , PEACH ROBERT J , ROWE TONY
IPC分类号： A61K20060101 , A61K6/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61K51/00 , A61K51/10 , A61P35/00 , C07H21/00 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C07K16/46 , C12N15/12 , C12Q1/68 , G01N33/574 , C07K16/00
CPC分类号： C07K14/70503 , A61K51/1027 , A61K51/1045 , C07K14/47 , C07K16/2803 , C07K16/30 , C07K2319/30
摘要： Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.
摘要翻译：公开了人IGSF9和LIV-1多肽和编码这种多肽的DNA（RNA）。公开的多肽和/或多核苷酸是特别有用的，其产生结合IGSF9或LIV-1的经修饰和天然的抗体。还公开了包含本发明的抗体，多肽和多核苷酸的药物组合物和疫苗。还公开了利用这些多肽鉴定所述多肽的配体，拮抗剂和激动剂的方法。最后，公开了包含上述组合物的方法用于肿瘤性疾病的治疗，诊断和/或预后。

4. 发明申请

WO2011017601A1 UPSET RECOVERY TRAINING USING A SUSTAINED-G MULTI-AXIS PLATFORM OR A CENTRIFUGE 审中-公开
标题翻译：使用持续的G多轴平台或中心的UPSET恢复训练
公开(公告)号：WO2011017601A1
公开(公告)日：2011-02-10
申请号：PCT/US2010/044684
申请日：2010-08-06
申请人： ENVIRONMENTAL TECTONICS CORPORATION , GLASER, Scott , KING, Glenn B. , LELAND, Richard, A.
发明人： GLASER, Scott , KING, Glenn B. , LELAND, Richard, A.
IPC分类号： G09B9/12
CPC分类号： G09B9/12
摘要： A process for providing upset recovery training (URT) includes using a sustained-G multi-axis platform (e.g., a centrifuge-based simulator). Various embodiments of the present invention address an important aspect of URT that is not present in the prior art, namely the placing of physiological stresses on the trainees during URT, such as sustained motions including, but not limited to, sustained, elevated G-forces and continuous rotational cues. Elevated, sustained, G-forces and continuous rotational cues can create many physiological challenges to aircrew. These challenges can include motion discomfort, disorientation, and visual disturbances. Embodiments of the present invention provide URT that includes physiological stresses on the pilot. If a pilot learns the correct procedures for recovery from an upset, as in the prior art URT programs, but cannot execute the procedures in the real world because he or she has not been prepared for the physiological environment to be faced, then safety is compromised. Embodiments of the present invention address this deficiency.
摘要翻译：用于提供不适的恢复训练（URT）的过程包括使用持续G多轴平台（例如，基于离心机的模拟器）。本发明的各种实施例解决了现有技术中不存在的URT的一个重要方面，即在URT期间将生理压力放置在学员身上，例如持续运动，包括但不限于持续升高的G力和连续旋转线索。升高，持续，G力和连续的旋转线索可能对机组人员造成许多生理挑战。这些挑战可能包括运动不适，定向障碍和视觉障碍。本发明的实施例提供了包括导频上的生理应力的URT。如果飞行员从现在的URT程序中学习正确的恢复程序，但是由于他或她没有为生理环境做好准备，所以无法执行现实世界中的程序，那么安全就会受到影响。本发明的实施例解决了这种缺陷。

5. 发明申请

WO2009043051A2 CD23 BINDING MOLECULES AND METHODS OF USE THEREOF 审中-公开
标题翻译： CD23结合分子及其使用方法
公开(公告)号：WO2009043051A2
公开(公告)日：2009-04-02
申请号：PCT/US2008078195
申请日：2008-09-29
申请人： BIOGEN IDEC INC , GLASER SCOTT , MILLER BRIAN ROBERT , LUGOVSKOY ALEXEY ALEXANDROVICH , DEMAREST STEPHEN , MACLAREN ANN , SNYDER WILLIAM B
发明人： GLASER SCOTT , MILLER BRIAN ROBERT , LUGOVSKOY ALEXEY ALEXANDROVICH , DEMAREST STEPHEN , MACLAREN ANN , SNYDER WILLIAM B
IPC分类号： C07K16/30 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2851 , A61K2039/505 , A61K2039/507 , C07K16/2893 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.
摘要翻译：本发明至少部分基于开发多价和稳定形式的CD23结合分子及其用于治疗免疫细胞病症（包括白血病或淋巴瘤如CLL）的方法。

6. 发明申请

WO2007109254A3 STABILIZED POLYPEPTIDE COMPOSITIONS 审中-公开
公开(公告)号：WO2007109254A3
公开(公告)日：2007-09-27
申请号：PCT/US2007/006883
申请日：2007-03-19
申请人： BIOGEN IDEC MA INC. , DEMAREST, Stephen , GLASER, Scott , MILLER, Brian, Robert , WU, Xiufeng , SNYDER, William, B. , WANG, Norman , CRONER, Lisa, J. , LUGOVSKOY, Alexey, Alexandrovich
发明人： DEMAREST, Stephen , GLASER, Scott , MILLER, Brian, Robert , WU, Xiufeng , SNYDER, William, B. , WANG, Norman , CRONER, Lisa, J. , LUGOVSKOY, Alexey, Alexandrovich
IPC分类号： C07K16/00 , C12N15/13 , C12N5/10 , A61K39/395 , G06F19/00
摘要： The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized. scFv and methods for making such stabilized molecules.

7. 发明申请

WO2006074397A3 CRIPTO BINDING MOLECULES 审中-公开
标题翻译： CRIPTO结合分子
公开(公告)号：WO2006074397A3
公开(公告)日：2006-12-28
申请号：PCT/US2006000502
申请日：2006-01-05
申请人： BIOGEN IDEC INC , GLASER SCOTT , VAN VLIJMEN HERMAN , LUGOVSKOY ALEXEY ALEXANDROVICH , SANICOLA-NADEL MICHELE , WU XIUFENG , GARBER ELLEN
发明人： GLASER SCOTT , VAN VLIJMEN HERMAN , LUGOVSKOY ALEXEY ALEXANDROVICH , SANICOLA-NADEL MICHELE , WU XIUFENG , GARBER ELLEN
IPC分类号： C07K16/30 , A61K31/00 , A61K39/395 , A61K47/48 , A61P35/00 , C07K16/46 , C12N5/10 , C12N15/13 , C12N15/85
CPC分类号： A61K51/1045 , A61K38/00 , A61K47/6803 , A61K47/6851 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/524 , C07K2317/53 , C07K2317/565 , C07K2317/567 , C07K2317/94
摘要： Humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
摘要翻译：抗CRIPTO抗体的人源化形式及其部分。在一个实施方案中，包含它们的这些抗体或多肽的可变区（例如，全长抗体或结构域缺失的抗体）可用于治疗诸如癌症的病症。

8. 发明申请

WO2006047357A3 HUMAN LY6-BIG MOLECULES AND METHODS OF USE 审中-公开
标题翻译：人LY6-大分子和使用方法
公开(公告)号：WO2006047357A3
公开(公告)日：2006-12-28
申请号：PCT/US2005038076
申请日：2005-10-24
申请人： BIOGEN IDEC INC , CHU PETER , DANIELS MARK , PEACH ROBERT , MCLACHLAN KAREN , JUNG JAEHO , GLASER SCOTT
发明人： CHU PETER , DANIELS MARK , PEACH ROBERT , MCLACHLAN KAREN , JUNG JAEHO , GLASER SCOTT
IPC分类号： C07H21/04 , A61K38/00 , C07K1/00 , C12N1/20 , C12P21/06
CPC分类号： C07K16/28 , C07K14/705
摘要： The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS.
摘要翻译：本发明涉及人Ly6-BIG分子及其在结肠癌，肺癌和其他癌症的诊断，预后和治疗方法中的用途，用于预防这种癌症的复发，以及用于自身免疫疾病的诊断，预后和治疗方法和艾滋病。

9. 发明申请

WO2004066933A2 COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1 审中-公开
标题翻译：使用IGSF9和LIV-1治疗癌症的组合物和方法
公开(公告)号：WO2004066933A2
公开(公告)日：2004-08-12
申请号：PCT/US2004/002044
申请日：2004-01-27
申请人： MCLACHLAN, Karen , GLASER, Scott , PEACH, Robert, J. , ROWE, Tony
发明人： MCLACHLAN, Karen , GLASER, Scott , PEACH, Robert, J. , ROWE, Tony
IPC分类号： A61K
CPC分类号： C07K14/70503 , A61K51/1027 , A61K51/1045 , C07K14/47 , C07K16/2803 , C07K16/30 , C07K2319/30
摘要： Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.
摘要翻译：公开了人IGSF9和LIV-1多肽和编码这种多肽的DNA（RNA）。公开的多肽和/或多核苷酸是特别有用的，其产生结合IGSF9或LIV-1的经修饰和天然的抗体。还公开了包含本发明的抗体，多肽和多核苷酸的药物组合物和疫苗。还公开了利用这些多肽鉴定所述多肽的配体，拮抗剂和激动剂的方法。最后，公开了包含上述组合物的方法用于肿瘤性疾病的治疗，诊断和/或预后。

10. 发明申请

WO2010051502A2 LIGHT TARGETING MOLECULES AND USES THEREOF 审中-公开
标题翻译：光靶分子及其用途
公开(公告)号：WO2010051502A2
公开(公告)日：2010-05-06
申请号：PCT/US2009062870
申请日：2009-10-30
申请人： BIOGEN IDEC INC , WANG XINZHONG , BAILLY VERONIQUE , GLASER SCOTT , LUGOVSKOY ALEXEY , FARRINGTON GRAHAM K , GRAFF CHRISTILYN
发明人： WANG XINZHONG , BAILLY VERONIQUE , GLASER SCOTT , LUGOVSKOY ALEXEY , FARRINGTON GRAHAM K , GRAFF CHRISTILYN
IPC分类号： A61K39/395 , A61P35/00 , C07K16/30 , C07K19/00 , C12N15/62
CPC分类号： C07K16/32 , A61K38/00 , A61K2039/505 , C07K14/525 , C07K16/2851 , C07K16/2869 , C07K2317/21 , C07K2317/55 , C07K2317/74 , C07K2317/77 , C07K2319/00 , C07K2319/32
摘要： LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.
摘要翻译：公开了靶向LIGHT的分子（例如LIGHT融合分子），抗HER2抗体分子，组合物，例如其药物组合物。还提供了使用这些分子来治疗，预防和/或诊断过度增殖性（例如肿瘤性）疾病或病症（包括但不限于癌症和转移瘤）的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式